All In Biotech

Drug Trial Radar · NCT05629585

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,174 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,174

Actual

Start

Nov 28, 2022

Primary completion

Sep 1, 2027

Study completion Feb 28, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo; SWOG Clinical Trials Partnerships, LLC
First posted
Nov 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.

Conditions

  • Breast Cancer

Interventions

  • Dato-DXdDrug

    Experimental drug. Provided in 100mg vials. IV infusion

  • DurvalumabDrug

    Experimental drug. Provided in 50mg vials. IV infusion

  • CapecitabineDrug

    Active Comparator. Tablet. Oral route of administration

  • PembrolizumabDrug

    Active Comparator. Provided in 100mg vials. IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICTTime frame: From randomisation to date of the event, up to 57 months from first subject in

Locations

276 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Springdale, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Costa Mesa, California

  • Research Site

    Duarte, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Irvine, California

  • Research Site

    La Jolla, California

  • Research Site

    Lakewood, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Newport Beach, California

  • Research Site

    Orange, California

  • Research Site

    Roseville, California

  • Research Site

    Upland, California

  • Research Site

    Vallejo, California

  • Research Site

    Denver, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Newark, Delaware

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Altamonte Springs, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Miami Beach, Florida

  • Research Site

    Tallahassee, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Athens, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Maywood, Illinois

  • Research Site

    Westwood, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Louisville, Kentucky

Showing 40 of 276 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.